Exciting New Potential Treatment for Malaria
Super Critical Extraction New Zealand & Australia Pty Limited
Press Release Australian and NZ Press Associations and others:
Exciting New Potential Treatment for Malaria
Super Critical Extraction New Zealand & Australia Pty
Limited (“SCENZA”) today announced the development of
two new and distinct nutraceutical treatment delivery
systems in the fight against Malaria. Each formulation
contains active ingredient artemisinin.
These delivery
systems are to be trialed immediately in Papua New
Guinea.
One treatment system is delivered in tablet form aimed at the adult market, the other in lozenge form with a lower dose of artemisinin, aimed at treating children. The active ingredient, artemisinin is an important component found in the Chinese herb, Artemisia Annua. SCENZA has a supply of high quality, super critically extracted artemisinin extracted at the company’s plant at Beechworth in Victoria.
Artemisinin is recognized as the pre-eminent natural substance contained in ACT’s or Artemisinin –based Combination Therapies being developed in the world-wide fight against malaria. These new formulations use several compounds in conjunction with the active ingredient, artemisinin to help reduce the odds of a mutation effect on the ability of artemisinin to fight the malaria parasite.
A nutraceutical formulation, which means the main ingredient comes from a natural plant extract, allows this to be a low cost remedy for alleviating the symptoms of this energy sapping tropical disease.
Many of the
countries affected by Malaria cannot afford high cost
pharmaceutical drugs in the fight against these tropical and
debilitating diseases hence the nutraceutical
formulation.
The company reports that it is working closely with doctors and naturopaths in Papua New Guinea to conduct a trial for its two new formulations. The company has finalized the specification, methodology and protocols of the a trials.
In anticipation of a successful trial, discussions are already well advanced with potential distributors for handling the introduction of these two new low cost remedies in Papua New Guinea.
ENDS